• NL close
• CH close
• SG close

The Eukaryotic Promoter Database (EPD) provides accurate transcription start site (TSS) information for promoters of 15 model organisms, from human to yeast to the malaria parasite Plasmodium falciparum. While the original database was a manually curated database based on published experiments, new promoter collections are now produced entirely automatically (under the name “EPDnew”) based on high-throughput transcript mapping data and high-quality gene annotation resources. Corresponding functional genomics data can be viewed in a genome browser, queried or analyzed via web interfaces, or exported in standard formats like FASTA or BED for subsequent analysis with other tools; of note, EPD is tightly integrated with two tool suites developed by our group: ChIP-Seq and Signal Search Analysis, for analysis of chromatin context and sequence motif respectively. EPD provides promoter viewers, designed with the aim of integrating and displaying information from different sources about, for instance, histone marks, transcription factor-binding sites or SNPs with known phenotypes. These viewers rely upon the UCSC genome browser as a visualization platform, which enables users to view data tracks from EPD jointly with tracks from UCSC or public track hubs.

TreatmentBank (TB) is a service provided by the Swiss Plazi GmbH to liberate data from scholarly publications, and convert, enhance, link, store, and disseminate it as Findable, Accessible, Interoperable and Reusable (FAIR) data. These data include taxonomic treatments, treatment citations, figures, tables, material citations and bibliographic reference. The data extraction processes can be highly automated to process entire journal back-issues as well as current publications. A quality control (QC) process as well as manual checks produce data fit to become reference deposits of treatments in Biodiversity Literature Repository (BLR), as well as daily uploads of treatment articles data sets to the Global Biodiversity Information Facility (GBIF), with persistent identifiers minted in BLR. Input formats can be printed to born-digital publications. All data are openly accessible in various formats and are searchable. Currently, BLR contains more than 650,000 treatments extracted from 66,000 articles, 400,000 figures and 1,040,000 material citations.

A public standards-compliant repository for gel-based proteomics data linked to protein identification published in the literature, and stores a collection of multi-species reference maps, with thousands of identified spots..

DANS Data Station Physical and Technical Sciences

Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.